#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	time	new	coref	4-9[8_0]
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Cancer is one of the most important and deadly diseases worldwide .
3-1	17-23	Cancer	abstract	new	coref	4-20
3-2	24-26	is	_	_	_	_
3-3	27-30	one	abstract[4]	new[4]	_	_
3-4	31-33	of	abstract[4]	new[4]	_	_
3-5	34-37	the	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-6	38-42	most	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-7	43-52	important	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-8	53-56	and	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-9	57-63	deadly	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-10	64-72	diseases	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-11	73-82	worldwide	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-12	83-84	.	_	_	_	_

#Text=Reports from the World Health Organization show that almost 1 in 6 deaths worldwide in 2018 were due to cancer .
4-1	85-92	Reports	abstract[6]	new[6]	_	_
4-2	93-97	from	abstract[6]	new[6]	_	_
4-3	98-101	the	abstract[6]|organization[7]	new[6]|new[7]	ana	5-10[0_7]
4-4	102-107	World	abstract[6]|organization[7]	new[6]|new[7]	_	_
4-5	108-114	Health	abstract[6]|organization[7]	new[6]|new[7]	_	_
4-6	115-127	Organization	abstract[6]|organization[7]	new[6]|new[7]	_	_
4-7	128-132	show	_	_	_	_
4-8	133-137	that	_	_	_	_
4-9	138-144	almost	time[8]	giv[8]	_	_
4-10	145-146	1	time[8]	giv[8]	_	_
4-11	147-149	in	time[8]	giv[8]	_	_
4-12	150-151	6	time[8]|event[9]	giv[8]|new[9]	_	_
4-13	152-158	deaths	time[8]|event[9]	giv[8]|new[9]	_	_
4-14	159-168	worldwide	time[8]|event[9]	giv[8]|new[9]	_	_
4-15	169-171	in	time[8]|event[9]	giv[8]|new[9]	_	_
4-16	172-176	2018	time[8]|event[9]|time	giv[8]|new[9]|new	_	_
4-17	177-181	were	_	_	_	_
4-18	182-185	due	_	_	_	_
4-19	186-188	to	_	_	_	_
4-20	189-195	cancer	abstract	giv	coref	5-15
4-21	196-197	.	_	_	_	_

#Text=Chemotherapy is a common approach for cancer treatment ; it uses drugs to kill cancer cells .
5-1	198-210	Chemotherapy	abstract	new	coref	5-3[13_0]
5-2	211-213	is	_	_	_	_
5-3	214-215	a	abstract[13]	giv[13]	coref	6-9[0_13]
5-4	216-222	common	abstract[13]	giv[13]	_	_
5-5	223-231	approach	abstract[13]	giv[13]	_	_
5-6	232-235	for	abstract[13]	giv[13]	_	_
5-7	236-242	cancer	abstract[13]|event[14]	giv[13]|new[14]	coref	20-16[119_14]
5-8	243-252	treatment	abstract[13]|event[14]	giv[13]|new[14]	_	_
5-9	253-254	;	_	_	_	_
5-10	255-257	it	organization	giv	_	_
5-11	258-262	uses	_	_	_	_
5-12	263-268	drugs	substance	new	coref	10-4[45_0]
5-13	269-271	to	_	_	_	_
5-14	272-276	kill	_	_	_	_
5-15	277-283	cancer	abstract|object[18]	giv|new[18]	coref|coref	8-19|8-19
5-16	284-289	cells	object[18]	new[18]	_	_
5-17	290-291	.	_	_	_	_

#Text=However , various limitations affect the efficiency of chemotherapy .
6-1	292-299	However	_	_	_	_
6-2	300-301	,	_	_	_	_
6-3	302-309	various	abstract[19]	new[19]	_	_
6-4	310-321	limitations	abstract[19]	new[19]	_	_
6-5	322-328	affect	_	_	_	_
6-6	329-332	the	abstract[20]	new[20]	coref	22-4[128_20]
6-7	333-343	efficiency	abstract[20]	new[20]	_	_
6-8	344-346	of	abstract[20]	new[20]	_	_
6-9	347-359	chemotherapy	abstract[20]|abstract	new[20]|giv	coref	12-1
6-10	360-361	.	_	_	_	_

#Text=For example , most chemotherapeutics possess poor aqueous solubility , harm normal cell toxicity due to the lack of selectivity , and cause multidrug resistance .
7-1	362-365	For	_	_	_	_
7-2	366-373	example	_	_	_	_
7-3	374-375	,	_	_	_	_
7-4	376-380	most	substance[22]	new[22]	_	_
7-5	381-398	chemotherapeutics	substance[22]	new[22]	_	_
7-6	399-406	possess	_	_	_	_
7-7	407-411	poor	abstract[24]	new[24]	coref	10-23[52_24]
7-8	412-419	aqueous	person|abstract[24]	new|new[24]	_	_
7-9	420-430	solubility	abstract[24]	new[24]	_	_
7-10	431-432	,	_	_	_	_
7-11	433-437	harm	_	_	_	_
7-12	438-444	normal	abstract[26]	new[26]	_	_
7-13	445-449	cell	place|abstract[26]	new|new[26]	_	_
7-14	450-458	toxicity	abstract[26]	new[26]	_	_
7-15	459-462	due	_	_	_	_
7-16	463-465	to	_	_	_	_
7-17	466-469	the	abstract[27]	new[27]	_	_
7-18	470-474	lack	abstract[27]	new[27]	_	_
7-19	475-477	of	abstract[27]	new[27]	_	_
7-20	478-489	selectivity	abstract[27]|abstract	new[27]|new	_	_
7-21	490-491	,	_	_	_	_
7-22	492-495	and	_	_	_	_
7-23	496-501	cause	_	_	_	_
7-24	502-511	multidrug	substance|abstract[30]	new|new[30]	coref|coref	16-16[92_30]|16-16[92_30]
7-25	512-522	resistance	abstract[30]	new[30]	_	_
7-26	523-524	.	_	_	_	_

#Text=To handle these shortcomings , researchers have proposed nano-particles as novel drug carriers to help patients cope with cancer .
8-1	525-527	To	_	_	_	_
8-2	528-534	handle	_	_	_	_
8-3	535-540	these	abstract[31]	new[31]	_	_
8-4	541-553	shortcomings	abstract[31]	new[31]	_	_
8-5	554-555	,	_	_	_	_
8-6	556-567	researchers	person	new	_	_
8-7	568-572	have	_	_	_	_
8-8	573-581	proposed	_	_	_	_
8-9	582-596	nano-particles	object	new	_	_
8-10	597-599	as	_	_	_	_
8-11	600-605	novel	_	_	_	_
8-12	606-610	drug	substance	new	coref	10-17
8-13	611-619	carriers	_	_	_	_
8-14	620-622	to	_	_	_	_
8-15	623-627	help	_	_	_	_
8-16	628-636	patients	person	new	coref	12-10[69_0]
8-17	637-641	cope	_	_	_	_
8-18	642-646	with	_	_	_	_
8-19	647-653	cancer	abstract	giv	coref	11-28
8-20	654-655	.	_	_	_	_

#Text=Nanoparticles , like vesicles , nanotubes , micelles , nanofibers , and nanosheet are typically commonly formed by amphiphilic copolymers via self-assembly .
9-1	656-669	Nanoparticles	object[37]	new[37]	coref	10-1[0_37]
9-2	670-671	,	object[37]	new[37]	_	_
9-3	672-676	like	object[37]	new[37]	_	_
9-4	677-685	vesicles	object[37]|object	new[37]|new	coref	23-1
9-5	686-687	,	object[37]	new[37]	_	_
9-6	688-697	nanotubes	object[37]|object	new[37]|new	_	_
9-7	698-699	,	object[37]	new[37]	_	_
9-8	700-708	micelles	object[37]|object	new[37]|new	_	_
9-9	709-710	,	object[37]	new[37]	_	_
9-10	711-721	nanofibers	object[37]|object	new[37]|new	_	_
9-11	722-723	,	object[37]	new[37]	_	_
9-12	724-727	and	object[37]	new[37]	_	_
9-13	728-737	nanosheet	object[37]|object	new[37]|new	_	_
9-14	738-741	are	_	_	_	_
9-15	742-751	typically	_	_	_	_
9-16	752-760	commonly	_	_	_	_
9-17	761-767	formed	_	_	_	_
9-18	768-770	by	_	_	_	_
9-19	771-782	amphiphilic	object[43]	new[43]	coref	25-1[141_43]
9-20	783-793	copolymers	object[43]	new[43]	_	_
9-21	794-797	via	_	_	_	_
9-22	798-811	self-assembly	_	_	_	_
9-23	812-813	.	_	_	_	_

#Text=Nanoparticles can encapsulate drugs via physical entrapment or solubilization to achieve various advantages , including controlled drug release , decreased cytotoxicity , increased aqueous solubility , and targeted action site .
10-1	814-827	Nanoparticles	object	giv	coref	11-3
10-2	828-831	can	_	_	_	_
10-3	832-843	encapsulate	_	_	_	_
10-4	844-849	drugs	substance[45]	giv[45]	coref	23-11[0_45]
10-5	850-853	via	substance[45]	giv[45]	_	_
10-6	854-862	physical	substance[45]|substance[46]	giv[45]|new[46]	_	_
10-7	863-873	entrapment	substance[45]|substance[46]	giv[45]|new[46]	_	_
10-8	874-876	or	substance[45]	giv[45]	_	_
10-9	877-891	solubilization	substance[45]|substance	giv[45]|new	_	_
10-10	892-894	to	_	_	_	_
10-11	895-902	achieve	_	_	_	_
10-12	903-910	various	abstract[48]	new[48]	_	_
10-13	911-921	advantages	abstract[48]	new[48]	_	_
10-14	922-923	,	abstract[48]	new[48]	_	_
10-15	924-933	including	abstract[48]	new[48]	_	_
10-16	934-944	controlled	abstract[48]|event[50]	new[48]|new[50]	coref	20-9[117_50]
10-17	945-949	drug	abstract[48]|substance|event[50]	new[48]|giv|new[50]	coref	11-11
10-18	950-957	release	abstract[48]|event[50]	new[48]|new[50]	_	_
10-19	958-959	,	abstract[48]	new[48]	_	_
10-20	960-969	decreased	abstract[48]|substance[51]	new[48]|new[51]	coref	22-8[129_51]
10-21	970-982	cytotoxicity	abstract[48]|substance[51]	new[48]|new[51]	_	_
10-22	983-984	,	abstract[48]	new[48]	_	_
10-23	985-994	increased	abstract[48]|abstract[52]	new[48]|giv[52]	_	_
10-24	995-1002	aqueous	abstract[48]|abstract[52]	new[48]|giv[52]	_	_
10-25	1003-1013	solubility	abstract[48]|abstract[52]	new[48]|giv[52]	_	_
10-26	1014-1015	,	abstract[48]	new[48]	_	_
10-27	1016-1019	and	abstract[48]	new[48]	_	_
10-28	1020-1028	targeted	abstract[48]|place[54]	new[48]|new[54]	_	_
10-29	1029-1035	action	abstract[48]|abstract|place[54]	new[48]|new|new[54]	_	_
10-30	1036-1040	site	abstract[48]|place[54]	new[48]|new[54]	_	_
10-31	1041-1042	.	_	_	_	_

#Text=Thus , nanoparticles have opened the door for developing effective drug delivery schemes and have shown substantial potential for applications in life-threatening disease treatments , such as cancer therapy .
11-1	1043-1047	Thus	_	_	_	_
11-2	1048-1049	,	_	_	_	_
11-3	1050-1063	nanoparticles	object	giv	coref	24-10[138_0]
11-4	1064-1068	have	_	_	_	_
11-5	1069-1075	opened	_	_	_	_
11-6	1076-1079	the	object[56]	new[56]	_	_
11-7	1080-1084	door	object[56]	new[56]	_	_
11-8	1085-1088	for	_	_	_	_
11-9	1089-1099	developing	_	_	_	_
11-10	1100-1109	effective	abstract[59]	new[59]	_	_
11-11	1110-1114	drug	substance|abstract[59]	giv|new[59]	coref	16-17
11-12	1115-1123	delivery	abstract|abstract[59]	new|new[59]	coref	20-6
11-13	1124-1131	schemes	abstract[59]	new[59]	_	_
11-14	1132-1135	and	_	_	_	_
11-15	1136-1140	have	_	_	_	_
11-16	1141-1146	shown	_	_	_	_
11-17	1147-1158	substantial	abstract[60]	new[60]	_	_
11-18	1159-1168	potential	abstract[60]	new[60]	_	_
11-19	1169-1172	for	abstract[60]	new[60]	_	_
11-20	1173-1185	applications	abstract[60]|abstract[61]	new[60]|new[61]	coref	24-7[136_61]
11-21	1186-1188	in	abstract[60]|abstract[61]	new[60]|new[61]	_	_
11-22	1189-1205	life-threatening	abstract[60]|abstract[61]|abstract[63]	new[60]|new[61]|new[63]	_	_
11-23	1206-1213	disease	abstract[60]|abstract[61]|abstract|abstract[63]	new[60]|new[61]|new|new[63]	_	_
11-24	1214-1224	treatments	abstract[60]|abstract[61]|abstract[63]	new[60]|new[61]|new[63]	_	_
11-25	1225-1226	,	abstract[60]|abstract[61]	new[60]|new[61]	_	_
11-26	1227-1231	such	abstract[60]|abstract[61]	new[60]|new[61]	_	_
11-27	1232-1234	as	abstract[60]|abstract[61]	new[60]|new[61]	_	_
11-28	1235-1241	cancer	abstract[60]|abstract[61]|abstract|abstract[65]	new[60]|new[61]|giv|new[65]	coref|coref|coref|coref	13-9|13-9[77_65]|13-9|13-9[77_65]
11-29	1242-1249	therapy	abstract[60]|abstract[61]|abstract[65]	new[60]|new[61]|new[65]	_	_
11-30	1250-1251	.	_	_	_	_

#Text=Chemotherapy usually causes a decline in immunity , causing cancer patients to suffer from bacterial infection or threatening their lives .
12-1	1252-1264	Chemotherapy	event	giv	_	_
12-2	1265-1272	usually	_	_	_	_
12-3	1273-1279	causes	_	_	_	_
12-4	1280-1281	a	abstract[67]	new[67]	_	_
12-5	1282-1289	decline	abstract[67]	new[67]	_	_
12-6	1290-1292	in	abstract[67]	new[67]	_	_
12-7	1293-1301	immunity	abstract[67]|abstract	new[67]|new	_	_
12-8	1302-1303	,	_	_	_	_
12-9	1304-1311	causing	_	_	_	_
12-10	1312-1318	cancer	person[69]	giv[69]	ana	12-19[0_69]
12-11	1319-1327	patients	person[69]	giv[69]	_	_
12-12	1328-1330	to	_	_	_	_
12-13	1331-1337	suffer	_	_	_	_
12-14	1338-1342	from	_	_	_	_
12-15	1343-1352	bacterial	object|abstract[71]	new|new[71]	coref|coref|coref|coref	13-4|13-4[75_71]|13-4|13-4[75_71]
12-16	1353-1362	infection	abstract[71]	new[71]	_	_
12-17	1363-1365	or	_	_	_	_
12-18	1366-1377	threatening	_	_	_	_
12-19	1378-1383	their	person|abstract[73]	giv|new[73]	_	_
12-20	1384-1389	lives	abstract[73]	new[73]	_	_
12-21	1390-1391	.	_	_	_	_

#Text=Therefore , avoiding bacterial infection is essential during cancer therapy .
13-1	1392-1401	Therefore	_	_	_	_
13-2	1402-1403	,	_	_	_	_
13-3	1404-1412	avoiding	_	_	_	_
13-4	1413-1422	bacterial	object|abstract[75]	giv|giv[75]	_	_
13-5	1423-1432	infection	abstract[75]	giv[75]	_	_
13-6	1433-1435	is	_	_	_	_
13-7	1436-1445	essential	_	_	_	_
13-8	1446-1452	during	_	_	_	_
13-9	1453-1459	cancer	abstract|event[77]	giv|giv[77]	coref|coref|coref|coref	28-16|28-16[168_77]|28-16|28-16[168_77]
13-10	1460-1467	therapy	event[77]	giv[77]	_	_
13-11	1468-1469	.	_	_	_	_

#Text=As a kind of novel antibacterial agent , antimicrobial peptides ( AMPs ) have gained increasing attention over the past few decades .
14-1	1470-1472	As	_	_	_	_
14-2	1473-1474	a	_	_	_	_
14-3	1475-1479	kind	person[78]	new[78]	_	_
14-4	1480-1482	of	person[78]	new[78]	_	_
14-5	1483-1488	novel	person[78]	new[78]	_	_
14-6	1489-1502	antibacterial	person[78]	new[78]	_	_
14-7	1503-1508	agent	person[78]	new[78]	_	_
14-8	1509-1510	,	_	_	_	_
14-9	1511-1524	antimicrobial	abstract[79]	new[79]	coref	18-5[105_79]
14-10	1525-1533	peptides	abstract[79]	new[79]	_	_
14-11	1534-1535	(	_	_	_	_
14-12	1536-1540	AMPs	object	new	coref	15-1
14-13	1541-1542	)	_	_	_	_
14-14	1543-1547	have	_	_	_	_
14-15	1548-1554	gained	_	_	_	_
14-16	1555-1565	increasing	abstract[81]	new[81]	_	_
14-17	1566-1575	attention	abstract[81]	new[81]	_	_
14-18	1576-1580	over	_	_	_	_
14-19	1581-1584	the	time[82]	new[82]	_	_
14-20	1585-1589	past	time[82]	new[82]	_	_
14-21	1590-1593	few	time[82]	new[82]	_	_
14-22	1594-1601	decades	time[82]	new[82]	_	_
14-23	1602-1603	.	_	_	_	_

#Text=AMPs exhibit excellent antibacterial capability and a unique antibacterial mechanism .
15-1	1604-1608	AMPs	object	giv	coref	16-1
15-2	1609-1616	exhibit	_	_	_	_
15-3	1617-1626	excellent	abstract[84]	new[84]	coref	26-16[149_84]
15-4	1627-1640	antibacterial	abstract[84]	new[84]	_	_
15-5	1641-1651	capability	abstract[84]	new[84]	_	_
15-6	1652-1655	and	_	_	_	_
15-7	1656-1657	a	abstract[85]	new[85]	coref	17-4[95_85]
15-8	1658-1664	unique	abstract[85]	new[85]	_	_
15-9	1665-1678	antibacterial	abstract[85]	new[85]	_	_
15-10	1679-1688	mechanism	abstract[85]	new[85]	_	_
15-11	1689-1690	.	_	_	_	_

#Text=AMPs achieve their bactericidal effect by physical disruption of bacterial membranes ; however , inducing bacterial drug resistance presents difficulty .
16-1	1691-1695	AMPs	object	giv	ana	16-3
16-2	1696-1703	achieve	_	_	_	_
16-3	1704-1709	their	object|abstract[88]	giv|new[88]	coref|coref	18-1[104_0]|18-1[104_0]
16-4	1710-1722	bactericidal	abstract[88]	new[88]	_	_
16-5	1723-1729	effect	abstract[88]	new[88]	_	_
16-6	1730-1732	by	_	_	_	_
16-7	1733-1741	physical	event[89]	new[89]	_	_
16-8	1742-1752	disruption	event[89]	new[89]	_	_
16-9	1753-1755	of	event[89]	new[89]	_	_
16-10	1756-1765	bacterial	event[89]|object[90]	new[89]|new[90]	_	_
16-11	1766-1775	membranes	event[89]|object[90]	new[89]|new[90]	_	_
16-12	1776-1777	;	_	_	_	_
16-13	1778-1785	however	_	_	_	_
16-14	1786-1787	,	_	_	_	_
16-15	1788-1796	inducing	_	_	_	_
16-16	1797-1806	bacterial	abstract[92]	giv[92]	_	_
16-17	1807-1811	drug	substance|abstract[92]	giv|giv[92]	coref	20-5
16-18	1812-1822	resistance	abstract[92]	giv[92]	_	_
16-19	1823-1831	presents	_	_	_	_
16-20	1832-1842	difficulty	abstract	new	_	_
16-21	1843-1844	.	_	_	_	_

#Text=Research illustrates that such a unique antibacterial mechanism is relevant to specific AMP structures , including cationic moieties such as lysine and hydrophobic moieties such as phenylalanine .
17-1	1845-1853	Research	abstract	new	_	_
17-2	1854-1865	illustrates	_	_	_	_
17-3	1866-1870	that	_	_	_	_
17-4	1871-1875	such	abstract[95]	giv[95]	coref	26-11[148_95]
17-5	1876-1877	a	abstract[95]	giv[95]	_	_
17-6	1878-1884	unique	abstract[95]	giv[95]	_	_
17-7	1885-1898	antibacterial	abstract[95]	giv[95]	_	_
17-8	1899-1908	mechanism	abstract[95]	giv[95]	_	_
17-9	1909-1911	is	_	_	_	_
17-10	1912-1920	relevant	_	_	_	_
17-11	1921-1923	to	_	_	_	_
17-12	1924-1932	specific	abstract[97]	new[97]	_	_
17-13	1933-1936	AMP	abstract|abstract[97]	new|new[97]	coref	20-1
17-14	1937-1947	structures	abstract[97]	new[97]	_	_
17-15	1948-1949	,	abstract[97]	new[97]	_	_
17-16	1950-1959	including	abstract[97]	new[97]	_	_
17-17	1960-1968	cationic	abstract[97]|abstract|substance[99]	new[97]|new|new[99]	_	_
17-18	1969-1977	moieties	abstract[97]|substance[99]	new[97]|new[99]	_	_
17-19	1978-1982	such	abstract[97]|substance[99]	new[97]|new[99]	_	_
17-20	1983-1985	as	abstract[97]|substance[99]	new[97]|new[99]	_	_
17-21	1986-1992	lysine	abstract[97]|substance[99]|substance|substance[101]	new[97]|new[99]|new|new[101]	coref|coref|coref|coref	21-10|21-10[125_101]|21-10|21-10[125_101]
17-22	1993-1996	and	abstract[97]|substance[99]|substance[101]	new[97]|new[99]|new[101]	_	_
17-23	1997-2008	hydrophobic	abstract[97]|substance[99]|substance[101]|substance[102]	new[97]|new[99]|new[101]|new[102]	coref	25-14[144_102]
17-24	2009-2017	moieties	abstract[97]|substance[99]|substance[101]|substance[102]	new[97]|new[99]|new[101]|new[102]	_	_
17-25	2018-2022	such	abstract[97]|substance[99]|substance[101]|substance[102]	new[97]|new[99]|new[101]|new[102]	_	_
17-26	2023-2025	as	abstract[97]|substance[99]|substance[101]|substance[102]	new[97]|new[99]|new[101]|new[102]	_	_
17-27	2026-2039	phenylalanine	abstract[97]|substance[99]|substance[101]|substance[102]|substance	new[97]|new[99]|new[101]|new[102]|new	coref	21-12
17-28	2040-2041	.	_	_	_	_

#Text=Lots of AMPs are amphiphilic peptides , namely , they are composed of hydrophobic and hydrophilic residues .
18-1	2042-2046	Lots	object[104]	giv[104]	coref	19-12[110_104]
18-2	2047-2049	of	object[104]	giv[104]	_	_
18-3	2050-2054	AMPs	object[104]	giv[104]	_	_
18-4	2055-2058	are	_	_	_	_
18-5	2059-2070	amphiphilic	abstract[105]	giv[105]	ana	18-10[0_105]
18-6	2071-2079	peptides	abstract[105]	giv[105]	_	_
18-7	2080-2081	,	_	_	_	_
18-8	2082-2088	namely	_	_	_	_
18-9	2089-2090	,	_	_	_	_
18-10	2091-2095	they	abstract	giv	_	_
18-11	2096-2099	are	_	_	_	_
18-12	2100-2108	composed	_	_	_	_
18-13	2109-2111	of	_	_	_	_
18-14	2112-2123	hydrophobic	substance[107]	new[107]	_	_
18-15	2124-2127	and	substance[107]	new[107]	_	_
18-16	2128-2139	hydrophilic	substance[107]	new[107]	_	_
18-17	2140-2148	residues	substance[107]	new[107]	_	_
18-18	2149-2150	.	_	_	_	_

#Text=AMP-nanoparticles can be prepared in an aqueous solution through self-assembly of these AMPs .
19-1	2151-2168	AMP-nanoparticles	object	new	_	_
19-2	2169-2172	can	_	_	_	_
19-3	2173-2175	be	_	_	_	_
19-4	2176-2184	prepared	_	_	_	_
19-5	2185-2187	in	_	_	_	_
19-6	2188-2190	an	substance[109]	new[109]	_	_
19-7	2191-2198	aqueous	substance[109]	new[109]	_	_
19-8	2199-2207	solution	substance[109]	new[109]	_	_
19-9	2208-2215	through	_	_	_	_
19-10	2216-2229	self-assembly	_	_	_	_
19-11	2230-2232	of	_	_	_	_
19-12	2233-2238	these	object[110]	giv[110]	coref	21-5[123_110]
19-13	2239-2243	AMPs	object[110]	giv[110]	_	_
19-14	2244-2245	.	_	_	_	_

#Text=AMP assemblies are ideal drug delivery systems exhibiting both drug release and antibacterial capabilities during cancer treatment .
20-1	2246-2249	AMP	object|object[112]	giv|new[112]	coref|coref	24-10|24-10
20-2	2250-2260	assemblies	object[112]	new[112]	_	_
20-3	2261-2264	are	_	_	_	_
20-4	2265-2270	ideal	_	_	_	_
20-5	2271-2275	drug	substance|object[115]	giv|new[115]	coref|coref|coref|coref	20-10|35-24[215_115]|20-10|35-24[215_115]
20-6	2276-2284	delivery	abstract|object[115]	giv|new[115]	coref	33-2
20-7	2285-2292	systems	object[115]	new[115]	_	_
20-8	2293-2303	exhibiting	_	_	_	_
20-9	2304-2308	both	event[117]	giv[117]	_	_
20-10	2309-2313	drug	substance|event[117]	giv|giv[117]	coref	34-16
20-11	2314-2321	release	event[117]	giv[117]	_	_
20-12	2322-2325	and	_	_	_	_
20-13	2326-2339	antibacterial	abstract[118]	new[118]	_	_
20-14	2340-2352	capabilities	abstract[118]	new[118]	_	_
20-15	2353-2359	during	_	_	_	_
20-16	2360-2366	cancer	event[119]	giv[119]	coref	34-19[204_119]
20-17	2367-2376	treatment	event[119]	giv[119]	_	_
20-18	2377-2378	.	_	_	_	_

#Text=Our group has reported several amphiphilic block AMPs containing lysine and phenylalanine .
21-1	2379-2382	Our	person|organization[121]	acc|new[121]	ana|ana	29-2|29-2
21-2	2383-2388	group	organization[121]	new[121]	_	_
21-3	2389-2392	has	_	_	_	_
21-4	2393-2401	reported	_	_	_	_
21-5	2402-2409	several	object[123]	giv[123]	coref	22-1[127_123]
21-6	2410-2421	amphiphilic	object[123]	giv[123]	_	_
21-7	2422-2427	block	object|object[123]	new|giv[123]	coref	30-13
21-8	2428-2432	AMPs	object[123]	giv[123]	_	_
21-9	2433-2443	containing	_	_	_	_
21-10	2444-2450	lysine	substance|substance[125]	giv|giv[125]	_	_
21-11	2451-2454	and	substance[125]	giv[125]	_	_
21-12	2455-2468	phenylalanine	substance[125]|substance	giv[125]|giv	_	_
21-13	2469-2470	.	_	_	_	_

#Text=These AMPs exhibit high bactericidal efficiency and low cytotoxicity .
22-1	2471-2476	These	object[127]	giv[127]	coref	23-4[131_127]
22-2	2477-2481	AMPs	object[127]	giv[127]	_	_
22-3	2482-2489	exhibit	_	_	_	_
22-4	2490-2494	high	abstract[128]	giv[128]	_	_
22-5	2495-2507	bactericidal	abstract[128]	giv[128]	_	_
22-6	2508-2518	efficiency	abstract[128]	giv[128]	_	_
22-7	2519-2522	and	_	_	_	_
22-8	2523-2526	low	substance[129]	giv[129]	coref	35-7[207_129]
22-9	2527-2539	cytotoxicity	substance[129]	giv[129]	_	_
22-10	2540-2541	.	_	_	_	_

#Text=Vesicles formed by these AMPs have good performance when carrying drugs .
23-1	2542-2550	Vesicles	object	giv	_	_
23-2	2551-2557	formed	_	_	_	_
23-3	2558-2560	by	_	_	_	_
23-4	2561-2566	these	object[131]	giv[131]	coref	25-9[0_131]
23-5	2567-2571	AMPs	object[131]	giv[131]	_	_
23-6	2572-2576	have	_	_	_	_
23-7	2577-2581	good	abstract[132]	new[132]	_	_
23-8	2582-2593	performance	abstract[132]	new[132]	_	_
23-9	2594-2598	when	_	_	_	_
23-10	2599-2607	carrying	_	_	_	_
23-11	2608-2613	drugs	substance	giv	_	_
23-12	2614-2615	.	_	_	_	_

#Text=Motivated by the excellent properties and promising applications of AMP nanoparticles , synthetic amphiphilic AMP – mimetic polymers are proposed .
24-1	2616-2625	Motivated	_	_	_	_
24-2	2626-2628	by	_	_	_	_
24-3	2629-2632	the	abstract[134]|abstract[135]	new[134]|new[135]	coref|coref|coref|coref	26-6[146_134]|26-6[147_135]|26-6[146_134]|26-6[147_135]
24-4	2633-2642	excellent	abstract[134]|abstract[135]	new[134]|new[135]	_	_
24-5	2643-2653	properties	abstract[134]|abstract[135]	new[134]|new[135]	_	_
24-6	2654-2657	and	abstract[135]	new[135]	_	_
24-7	2658-2667	promising	abstract[135]|abstract[136]	new[135]|giv[136]	coref	35-31[216_136]
24-8	2668-2680	applications	abstract[135]|abstract[136]	new[135]|giv[136]	_	_
24-9	2681-2683	of	abstract[135]|abstract[136]	new[135]|giv[136]	_	_
24-10	2684-2687	AMP	abstract[135]|abstract[136]|abstract|object[138]	new[135]|giv[136]|giv|giv[138]	coref|coref|coref|coref	24-13[139_0]|26-21[0_138]|24-13[139_0]|26-21[0_138]
24-11	2688-2701	nanoparticles	abstract[135]|abstract[136]|object[138]	new[135]|giv[136]|giv[138]	_	_
24-12	2702-2703	,	abstract[135]|abstract[136]|object[138]	new[135]|giv[136]|giv[138]	_	_
24-13	2704-2713	synthetic	abstract[135]|abstract[136]|object[138]|abstract[139]	new[135]|giv[136]|giv[138]|giv[139]	coref	29-11[0_139]
24-14	2714-2725	amphiphilic	abstract[135]|abstract[136]|object[138]|abstract[139]	new[135]|giv[136]|giv[138]|giv[139]	_	_
24-15	2726-2729	AMP	abstract[135]|abstract[136]|object[138]|abstract[139]	new[135]|giv[136]|giv[138]|giv[139]	_	_
24-16	2730-2731	–	_	_	_	_
24-17	2732-2739	mimetic	object[140]	new[140]	_	_
24-18	2740-2748	polymers	object[140]	new[140]	_	_
24-19	2749-2752	are	_	_	_	_
24-20	2753-2761	proposed	_	_	_	_
24-21	2762-2763	.	_	_	_	_

#Text=These amphiphilic copolymers stimulate the structural features of AMPs , that is , cationic and hydrophobic moieties .
25-1	2764-2769	These	object[141]	giv[141]	coref	26-1[145_141]
25-2	2770-2781	amphiphilic	object[141]	giv[141]	_	_
25-3	2782-2792	copolymers	object[141]	giv[141]	_	_
25-4	2793-2802	stimulate	_	_	_	_
25-5	2803-2806	the	abstract[142]	new[142]	_	_
25-6	2807-2817	structural	abstract[142]	new[142]	_	_
25-7	2818-2826	features	abstract[142]	new[142]	_	_
25-8	2827-2829	of	abstract[142]	new[142]	_	_
25-9	2830-2834	AMPs	abstract[142]|object	new[142]|giv	coref	26-28[152_0]
25-10	2835-2836	,	_	_	_	_
25-11	2837-2841	that	_	_	_	_
25-12	2842-2844	is	_	_	_	_
25-13	2845-2846	,	_	_	_	_
25-14	2847-2855	cationic	substance[144]	giv[144]	_	_
25-15	2856-2859	and	substance[144]	giv[144]	_	_
25-16	2860-2871	hydrophobic	substance[144]	giv[144]	_	_
25-17	2872-2880	moieties	substance[144]	giv[144]	_	_
25-18	2881-2882	.	_	_	_	_

#Text=Amphiphilic copolymers not only possess good properties , such as a unique bactericidal mechanism , the capability for self-assembly into nanoparticles that are similar to those of natural AMPs , but also show more convenient synthesis strategy than natural AMPs .
26-1	2883-2894	Amphiphilic	object[145]	giv[145]	coref	27-18[161_145]
26-2	2895-2905	copolymers	object[145]	giv[145]	_	_
26-3	2906-2909	not	_	_	_	_
26-4	2910-2914	only	_	_	_	_
26-5	2915-2922	possess	_	_	_	_
26-6	2923-2927	good	abstract[146]|abstract[147]	giv[146]|giv[147]	coref|coref|coref|coref	35-2[205_146]|35-2[206_147]|35-2[205_146]|35-2[206_147]
26-7	2928-2938	properties	abstract[146]|abstract[147]	giv[146]|giv[147]	_	_
26-8	2939-2940	,	abstract[146]|abstract[147]	giv[146]|giv[147]	_	_
26-9	2941-2945	such	abstract[146]|abstract[147]	giv[146]|giv[147]	_	_
26-10	2946-2948	as	abstract[146]|abstract[147]	giv[146]|giv[147]	_	_
26-11	2949-2950	a	abstract[146]|abstract[147]|abstract[148]	giv[146]|giv[147]|giv[148]	_	_
26-12	2951-2957	unique	abstract[146]|abstract[147]|abstract[148]	giv[146]|giv[147]|giv[148]	_	_
26-13	2958-2970	bactericidal	abstract[146]|abstract[147]|abstract[148]	giv[146]|giv[147]|giv[148]	_	_
26-14	2971-2980	mechanism	abstract[146]|abstract[147]|abstract[148]	giv[146]|giv[147]|giv[148]	_	_
26-15	2981-2982	,	abstract[147]	giv[147]	_	_
26-16	2983-2986	the	abstract[147]|abstract[149]	giv[147]|giv[149]	ana	26-26[151_149]
26-17	2987-2997	capability	abstract[147]|abstract[149]	giv[147]|giv[149]	_	_
26-18	2998-3001	for	abstract[147]|abstract[149]	giv[147]|giv[149]	_	_
26-19	3002-3015	self-assembly	abstract[147]|abstract[149]	giv[147]|giv[149]	_	_
26-20	3016-3020	into	abstract[147]|abstract[149]	giv[147]|giv[149]	_	_
26-21	3021-3034	nanoparticles	abstract[147]|abstract[149]|object	giv[147]|giv[149]|giv	coref	31-6
26-22	3035-3039	that	_	_	_	_
26-23	3040-3043	are	_	_	_	_
26-24	3044-3051	similar	_	_	_	_
26-25	3052-3054	to	_	_	_	_
26-26	3055-3060	those	abstract[151]	giv[151]	coref	28-1[165_151]
26-27	3061-3063	of	abstract[151]	giv[151]	_	_
26-28	3064-3071	natural	abstract[151]|object[152]	giv[151]|giv[152]	coref	26-39[155_152]
26-29	3072-3076	AMPs	abstract[151]|object[152]	giv[151]|giv[152]	_	_
26-30	3077-3078	,	_	_	_	_
26-31	3079-3082	but	_	_	_	_
26-32	3083-3087	also	_	_	_	_
26-33	3088-3092	show	_	_	_	_
26-34	3093-3097	more	abstract[154]	new[154]	_	_
26-35	3098-3108	convenient	abstract[154]	new[154]	_	_
26-36	3109-3118	synthesis	abstract|abstract[154]	new|new[154]	_	_
26-37	3119-3127	strategy	abstract[154]	new[154]	_	_
26-38	3128-3132	than	abstract[154]	new[154]	_	_
26-39	3133-3140	natural	abstract[154]|object[155]	new[154]|giv[155]	_	_
26-40	3141-3145	AMPs	abstract[154]|object[155]	new[154]|giv[155]	_	_
26-41	3146-3147	.	_	_	_	_

#Text=In previous work , Zhou et al. have reported the minimal inhibition concentration ( MIC ) of amphiphilic copolymers was less than 32 μg/mL against both Gram-negative and Gram-positive bacteria .
27-1	3148-3150	In	_	_	_	_
27-2	3151-3159	previous	abstract[156]	new[156]	coref	29-2[170_156]
27-3	3160-3164	work	abstract[156]	new[156]	_	_
27-4	3165-3166	,	_	_	_	_
27-5	3167-3171	Zhou	person	new	_	_
27-6	3172-3174	et	_	_	_	_
27-7	3175-3178	al.	_	_	_	_
27-8	3179-3183	have	_	_	_	_
27-9	3184-3192	reported	_	_	_	_
27-10	3193-3196	the	quantity[159]	new[159]	_	_
27-11	3197-3204	minimal	quantity[159]	new[159]	_	_
27-12	3205-3215	inhibition	event|quantity[159]	new|new[159]	_	_
27-13	3216-3229	concentration	quantity[159]	new[159]	_	_
27-14	3230-3231	(	_	_	_	_
27-15	3232-3235	MIC	abstract	new	_	_
27-16	3236-3237	)	_	_	_	_
27-17	3238-3240	of	_	_	_	_
27-18	3241-3252	amphiphilic	object[161]	giv[161]	coref	29-11[174_161]
27-19	3253-3263	copolymers	object[161]	giv[161]	_	_
27-20	3264-3267	was	_	_	_	_
27-21	3268-3272	less	quantity[162]	new[162]	_	_
27-22	3273-3277	than	quantity[162]	new[162]	_	_
27-23	3278-3280	32	quantity[162]	new[162]	_	_
27-24	3281-3286	μg/mL	quantity[162]	new[162]	_	_
27-25	3287-3294	against	quantity[162]	new[162]	_	_
27-26	3295-3299	both	quantity[162]|substance[163]	new[162]|new[163]	_	_
27-27	3300-3313	Gram-negative	quantity[162]|substance[163]	new[162]|new[163]	_	_
27-28	3314-3317	and	quantity[162]	new[162]	_	_
27-29	3318-3331	Gram-positive	quantity[162]|animal[164]	new[162]|new[164]	coref	29-21[178_164]
27-30	3332-3340	bacteria	quantity[162]|animal[164]	new[162]|new[164]	_	_
27-31	3341-3342	.	_	_	_	_

#Text=The broad antibacterial capability has been proved , which will play a vital role in cancer therapy .
28-1	3343-3346	The	abstract[165]	giv[165]	_	_
28-2	3347-3352	broad	abstract[165]	giv[165]	_	_
28-3	3353-3366	antibacterial	abstract[165]	giv[165]	_	_
28-4	3367-3377	capability	abstract[165]	giv[165]	_	_
28-5	3378-3381	has	_	_	_	_
28-6	3382-3386	been	_	_	_	_
28-7	3387-3393	proved	_	_	_	_
28-8	3394-3395	,	_	_	_	_
28-9	3396-3401	which	_	_	_	_
28-10	3402-3406	will	_	_	_	_
28-11	3407-3411	play	_	_	_	_
28-12	3412-3413	a	abstract[166]	new[166]	_	_
28-13	3414-3419	vital	abstract[166]	new[166]	_	_
28-14	3420-3424	role	abstract[166]	new[166]	_	_
28-15	3425-3427	in	abstract[166]	new[166]	_	_
28-16	3428-3434	cancer	abstract[166]|abstract|abstract[168]	new[166]|giv|giv[168]	_	_
28-17	3435-3442	therapy	abstract[166]|abstract[168]	new[166]|giv[168]	_	_
28-18	3443-3444	.	_	_	_	_

#Text=In our previous work , a series of amphiphilic mimicked AMP copolymers , PCL16- b -Kn , which can inhibit both Gram-negative and Gram-positive bacteria .
29-1	3445-3447	In	_	_	_	_
29-2	3448-3451	our	person|abstract[170]	giv|giv[170]	coref|ana|coref|ana	30-2[179_170]|30-6|30-2[179_170]|30-6
29-3	3452-3460	previous	abstract[170]	giv[170]	_	_
29-4	3461-3465	work	abstract[170]	giv[170]	_	_
29-5	3466-3467	,	_	_	_	_
29-6	3468-3469	a	abstract[171]	new[171]	_	_
29-7	3470-3476	series	abstract[171]	new[171]	_	_
29-8	3477-3479	of	abstract[171]	new[171]	_	_
29-9	3480-3491	amphiphilic	abstract[171]|abstract	new[171]|new	_	_
29-10	3492-3500	mimicked	_	_	_	_
29-11	3501-3504	AMP	abstract|object[174]	giv|giv[174]	appos|appos	29-14[0_174]|29-14[0_174]
29-12	3505-3515	copolymers	object[174]	giv[174]	_	_
29-13	3516-3517	,	_	_	_	_
29-14	3518-3524	PCL16-	abstract	giv	appos	29-15[177_0]
29-15	3525-3526	b	place|abstract[177]	new|giv[177]	coref|coref	30-12[183_177]|30-12[183_177]
29-16	3527-3530	-Kn	abstract[177]	giv[177]	_	_
29-17	3531-3532	,	_	_	_	_
29-18	3533-3538	which	_	_	_	_
29-19	3539-3542	can	_	_	_	_
29-20	3543-3550	inhibit	_	_	_	_
29-21	3551-3555	both	animal[178]	giv[178]	_	_
29-22	3556-3569	Gram-negative	animal[178]	giv[178]	_	_
29-23	3570-3573	and	animal[178]	giv[178]	_	_
29-24	3574-3587	Gram-positive	animal[178]	giv[178]	_	_
29-25	3588-3596	bacteria	animal[178]	giv[178]	_	_
29-26	3597-3598	.	_	_	_	_

#Text=In the present work , we studied the self-assembling behavior of these block copolymers in aqueous solutions .
30-1	3599-3601	In	_	_	_	_
30-2	3602-3605	the	abstract[179]	giv[179]	_	_
30-3	3606-3613	present	abstract[179]	giv[179]	_	_
30-4	3614-3618	work	abstract[179]	giv[179]	_	_
30-5	3619-3620	,	_	_	_	_
30-6	3621-3623	we	person	giv	_	_
30-7	3624-3631	studied	_	_	_	_
30-8	3632-3635	the	abstract[181]	new[181]	_	_
30-9	3636-3651	self-assembling	abstract[181]	new[181]	_	_
30-10	3652-3660	behavior	abstract[181]	new[181]	_	_
30-11	3661-3663	of	abstract[181]	new[181]	_	_
30-12	3664-3669	these	abstract[181]|object[183]	new[181]|giv[183]	coref	34-6[202_183]
30-13	3670-3675	block	abstract[181]|object|object[183]	new[181]|giv|giv[183]	_	_
30-14	3676-3686	copolymers	abstract[181]|object[183]	new[181]|giv[183]	_	_
30-15	3687-3689	in	abstract[181]|object[183]	new[181]|giv[183]	_	_
30-16	3690-3697	aqueous	abstract[181]|object[183]|substance[184]	new[181]|giv[183]|new[184]	_	_
30-17	3698-3707	solutions	abstract[181]|object[183]|substance[184]	new[181]|giv[183]|new[184]	_	_
30-18	3708-3709	.	_	_	_	_

#Text=The morphologies and sizes of nanoparticles were characterized by transmission electron microscopy ( TEM ) and dynamic light scattering ( DLS ) , respectively .
31-1	3710-3713	The	person[185]	new[185]	_	_
31-2	3714-3726	morphologies	person[185]	new[185]	_	_
31-3	3727-3730	and	_	_	_	_
31-4	3731-3736	sizes	quantity[186]	new[186]	_	_
31-5	3737-3739	of	quantity[186]	new[186]	_	_
31-6	3740-3753	nanoparticles	quantity[186]|object	new[186]|giv	coref	35-17[212_0]
31-7	3754-3758	were	_	_	_	_
31-8	3759-3772	characterized	_	_	_	_
31-9	3773-3775	by	_	_	_	_
31-10	3776-3788	transmission	_	_	_	_
31-11	3789-3797	electron	substance|object[189]	new|new[189]	_	_
31-12	3798-3808	microscopy	object[189]	new[189]	_	_
31-13	3809-3810	(	_	_	_	_
31-14	3811-3814	TEM	abstract	new	_	_
31-15	3815-3816	)	_	_	_	_
31-16	3817-3820	and	_	_	_	_
31-17	3821-3828	dynamic	abstract[192]	new[192]	appos	31-21[0_192]
31-18	3829-3834	light	object|abstract[192]	new|new[192]	_	_
31-19	3835-3845	scattering	abstract[192]	new[192]	_	_
31-20	3846-3847	(	_	_	_	_
31-21	3848-3851	DLS	abstract	giv	_	_
31-22	3852-3853	)	_	_	_	_
31-23	3854-3855	,	_	_	_	_
31-24	3856-3868	respectively	_	_	_	_
31-25	3869-3870	.	_	_	_	_

#Text=Critical vesiculation concentrations ( CVCs ) were also studied .
32-1	3871-3879	Critical	abstract[194]	new[194]	appos	32-5[0_194]
32-2	3880-3892	vesiculation	abstract[194]	new[194]	_	_
32-3	3893-3907	concentrations	abstract[194]	new[194]	_	_
32-4	3908-3909	(	_	_	_	_
32-5	3910-3914	CVCs	abstract	giv	_	_
32-6	3915-3916	)	_	_	_	_
32-7	3917-3921	were	_	_	_	_
32-8	3922-3926	also	_	_	_	_
32-9	3927-3934	studied	_	_	_	_
32-10	3935-3936	.	_	_	_	_

#Text=Drug delivery potential was investigated by in vitro and intracellular doxorubicin ( DOX)-release experiments .
33-1	3937-3941	Drug	abstract[197]	new[197]	_	_
33-2	3942-3950	delivery	abstract|abstract[197]	giv|new[197]	coref	35-28
33-3	3951-3960	potential	abstract[197]	new[197]	_	_
33-4	3961-3964	was	_	_	_	_
33-5	3965-3977	investigated	_	_	_	_
33-6	3978-3980	by	_	_	_	_
33-7	3981-3983	in	_	_	_	_
33-8	3984-3989	vitro	_	_	_	_
33-9	3990-3993	and	_	_	_	_
33-10	3994-4007	intracellular	abstract[198]	new[198]	_	_
33-11	4008-4019	doxorubicin	abstract[198]	new[198]	_	_
33-12	4020-4021	(	_	_	_	_
33-13	4022-4034	DOX)-release	event[199]	new[199]	_	_
33-14	4035-4046	experiments	event[199]	new[199]	_	_
33-15	4047-4048	.	_	_	_	_

#Text=Based on the results , amphiphilic diblock copolymers PCL16- b -Kn could serve as efficient drug carriers for cancer treatment .
34-1	4049-4054	Based	_	_	_	_
34-2	4055-4057	on	_	_	_	_
34-3	4058-4061	the	abstract[200]	new[200]	_	_
34-4	4062-4069	results	abstract[200]	new[200]	_	_
34-5	4070-4071	,	_	_	_	_
34-6	4072-4083	amphiphilic	object[202]	giv[202]	_	_
34-7	4084-4091	diblock	abstract|object[202]	new|giv[202]	coref	35-18
34-8	4092-4102	copolymers	object[202]	giv[202]	_	_
34-9	4103-4109	PCL16-	object[202]	giv[202]	_	_
34-10	4110-4111	b	object[202]	giv[202]	_	_
34-11	4112-4115	-Kn	object[202]	giv[202]	_	_
34-12	4116-4121	could	_	_	_	_
34-13	4122-4127	serve	_	_	_	_
34-14	4128-4130	as	_	_	_	_
34-15	4131-4140	efficient	_	_	_	_
34-16	4141-4145	drug	substance	giv	coref	35-27
34-17	4146-4154	carriers	_	_	_	_
34-18	4155-4158	for	_	_	_	_
34-19	4159-4165	cancer	event[204]	giv[204]	_	_
34-20	4166-4175	treatment	event[204]	giv[204]	_	_
34-21	4176-4177	.	_	_	_	_

#Text=Given the excellent antibacterial properties and low cytotoxicity of PCL16- b -Kn in previous works , such diblock copolymer nanoparticles can be ideal “ armed ” drug delivery systems for applications in nanomedical fields .
35-1	4178-4183	Given	_	_	_	_
35-2	4184-4187	the	abstract[205]|abstract[206]	giv[205]|giv[206]	_	_
35-3	4188-4197	excellent	abstract[205]|abstract[206]	giv[205]|giv[206]	_	_
35-4	4198-4211	antibacterial	abstract[205]|abstract[206]	giv[205]|giv[206]	_	_
35-5	4212-4222	properties	abstract[205]|abstract[206]	giv[205]|giv[206]	_	_
35-6	4223-4226	and	abstract[206]	giv[206]	_	_
35-7	4227-4230	low	abstract[206]|substance[207]	giv[206]|giv[207]	_	_
35-8	4231-4243	cytotoxicity	abstract[206]|substance[207]	giv[206]|giv[207]	_	_
35-9	4244-4246	of	abstract[206]|substance[207]	giv[206]|giv[207]	_	_
35-10	4247-4253	PCL16-	abstract[206]|substance[207]|abstract[208]	giv[206]|giv[207]|new[208]	_	_
35-11	4254-4255	b	abstract[206]|substance[207]|abstract[208]	giv[206]|giv[207]|new[208]	_	_
35-12	4256-4259	-Kn	abstract[206]|substance[207]|abstract[208]	giv[206]|giv[207]|new[208]	_	_
35-13	4260-4262	in	abstract[206]|substance[207]|abstract[208]	giv[206]|giv[207]|new[208]	_	_
35-14	4263-4271	previous	abstract[206]|substance[207]|abstract[208]|abstract[209]	giv[206]|giv[207]|new[208]|new[209]	_	_
35-15	4272-4277	works	abstract[206]|substance[207]|abstract[208]|abstract[209]	giv[206]|giv[207]|new[208]|new[209]	_	_
35-16	4278-4279	,	_	_	_	_
35-17	4280-4284	such	object[212]	giv[212]	_	_
35-18	4285-4292	diblock	abstract|object[212]	giv|giv[212]	_	_
35-19	4293-4302	copolymer	person|object[212]	new|giv[212]	_	_
35-20	4303-4316	nanoparticles	object[212]	giv[212]	_	_
35-21	4317-4320	can	_	_	_	_
35-22	4321-4323	be	_	_	_	_
35-23	4324-4329	ideal	_	_	_	_
35-24	4330-4331	“	object[215]	giv[215]	_	_
35-25	4332-4337	armed	object[215]	giv[215]	_	_
35-26	4338-4339	”	object[215]	giv[215]	_	_
35-27	4340-4344	drug	substance|object[215]	giv|giv[215]	_	_
35-28	4345-4353	delivery	abstract|object[215]	giv|giv[215]	_	_
35-29	4354-4361	systems	object[215]	giv[215]	_	_
35-30	4362-4365	for	object[215]	giv[215]	_	_
35-31	4366-4378	applications	object[215]|abstract[216]	giv[215]|giv[216]	_	_
35-32	4379-4381	in	object[215]|abstract[216]	giv[215]|giv[216]	_	_
35-33	4382-4393	nanomedical	object[215]|abstract[216]|abstract[217]	giv[215]|giv[216]|new[217]	_	_
35-34	4394-4400	fields	object[215]|abstract[216]|abstract[217]	giv[215]|giv[216]|new[217]	_	_
35-35	4401-4402	.	_	_	_	_
